Central Nervous System Tumors
A central nervous system (CNS) tumor begins when healthy cells in the brain or the spinal cord change and grow out of control, forming a mass, or tumor. If the tumor is malignant, it can spread to other parts of the body or brain, effecting a child’s thought processes and movements.
Our neuro-oncology team leads many different CNS tumor trials in coordination with sites around the world testing combinations of existing treatments, new approaches to radiation therapy or surgery, and new ways to relieve symptoms and side effects during treatment.
Protocol ID: Y-mAbs 101
Disease: NBL
Who can participate?: Patients must be b/t the ages of birth and 18 yr at the time of screening. Life expectancy of at least 3 months. Must have a histologically confirmed dx of NB w/ relapse in the CNS or LM. Must have stable systemic disease not requiring chemo/ immunotherapy as judged by the investigator.
Lead Researcher: Keri A. StrebyProtocol ID: BXQ-350.AD
Diseases: Diffuse Midline Glioma and Diffuse intrinsic pontine glioma (DIPG)
Who Can Participate?: New diagnosis, ages 1 to 30
Lead Researcher: Maryam Fouladi, MD
Protocol ID: CONNECT1702
Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG)
Who Can Participate?: New diagnosis, ages 1 to 21
Lead Researcher: Maryam Foudladi, MD
Protocol ID: ANBL1821
Disease: NBL
Who can participate?: Patients ≥ 1 year of age at the time of enrollment are eligible for this study. Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines at the time of initial diagnosis. Patients must have ONE of the following:
- First episode of recurrent disease following completion of aggressive multi-drug frontline therapy.
- First episode of progressive disease during aggressive multi-drug frontline therapy.
- Primary resistant/refractory disease
Lead Researcher: Mark A. Ranalli
Protocol ID: ACNS1723
Diseases: CNS Tumors High Grade Glioma (HGG)
Who Can Participate?: New diagnosis, ages 3 to 21
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ACNS1721
Disease: CNS
Who can participate?: Stratum 2 (IDH mutant): Patients must be ≥ 3 years of age and ≤ 25 years of age at the time of enrollment. Patients must have eligibility confirmed by rapid central pathology and central molecular screening reviews performed on APEC14B1 (see Section 3.1): Newly-diagnosed high-grade glioma such as anaplastic astrocytoma or glioblastoma, Negative results for H3 K27M by immunohistochemistry (IHC), Negative results for BRAFV600 mutation by Next-Generation Sequencing (NGS)."
Lead Researcher: Mark A. Ranalli
Protocol ID: ACNS1833
Diseases: CNS Tumors and Low Grade Glioma (LGG)
Who Can Participate?: Ages 2 to 21
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ACNS1831
Diseases: CNS Tumors, Low Grade Glioma (LGG), and Neurofibromatosis
Who Can Participate?: New diagnosis, ages 2 to 21
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: NANT 2013-01
Disease: NBL
Who can participate?: Must be ≤ 30 yrs of age. Diagnosis of HR neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. Recurrent/progressive, refractory or persistent disease based upon the response to prior therapy according to the protocol's guidelines.
Lead Researcher: Keri A. Streby
Protocol ID: PNOC008
Disease: High Grade Glioma (HGG)
Who Can Participate?: New diagnosis, ages 0 to 21
Lead Researcher: Diana S. Osorio, MD
Protocol ID: PNOC013
Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG)
Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 25
Lead Researcher: Diana S. Osorio, MD
Protocol ID: c cc
Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Medulloblastoma
Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 39
Lead Researcher: Diana S. Osorio, MD
Protocol ID: Head Start 4
Diseases: CNS Tumors and Medulloblastoma
Who Can Participate?: New diagnosis, ages 0 to 9
Lead Researcher: Randal S. Olshefski, MD
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Enrollment ANBL00B1 or APEC14B1; less than 30; dx NBL high risk with no prior systemic therapy.
Lead Researcher: Mark A. Ranalli
Protocol ID: PBTB
Diseases: CNS Tumors
Who Can Participate?: Ages 0 to 21
Lead Researcher: Diana S. Osorio, MD
Protocol ID: ANBL00B1
Disease: NBL
Who can participate?: All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study.
Lead Researcher: Mark A. Ranalli
Protocol ID: APEC1621K
Diseases: CNS Tumors, Langerhans cell histiocytosis (LCH), Neuroblastoma (NBL), Non-Hodgkin lymphoma (NHL), and Sarcoma
Who Can Participate?: Replapse/Refractory, age 1 to 21
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: APEC1621M
Diseases: CNS Tumors, Carcinoma, Diffuse intrinsic pontine glioma (DIPG), Ewing Sarcoma (EWS), Ganglioneuroblastoma (GBN), Germ cell tumor, High Grade Glioma (HGG), Low Grade Glioma (LGG), Medulloblastoma, Neuroblastoma (NBL), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Osteosarcoma (OS), Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Synovial sarcoma, and Wilms tumor
Who Can Participate?: Ages 1 to 21
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: PNOC005
Diseases: Atypical Teratoid Rhabdoid Tumor, CNS Tumors, and Medulloblastoma
Who Can Participate?: Replase/Refractory, ages 1 to 39
Lead Researcher: Diana S. Osorio, MD
Protocol ID: PNOC007
Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Low Grade Glioma (LGG)
Who Can Participate?: New diagnosis, ages 3 to 21
Lead Researcher: Diana S. Osorio, MD
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Must be enrolled on ANBL00B1 or APEC14B1; new diagnosed NBL or ganglioneuroblastoma; >1 y <30y age.
Lead Researcher: Mark A. Ranalli
Protocol ID: ANBL1232
Disease: NBL
Who can participate?: < 12 months of age at diagnosis with INRG Stage L1 or < 18 months of age at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma.
Lead Researcher: Mark A. Ranalli
Protocol ID: ALTE15N2
Disease: NBL
Who can participate?: Study Patients must have been enrolled on COG Neuroblastoma Biology Study ANBL00B1. Patients must be ≥ 5 and ≤ 50 years of age at study enrollment. Patient must have been diagnosed with high-risk neuroblastoma per ANBL00B1 definition. Patient must have been diagnosed on or after January 1, 2000. At least 5 years must have elapsed since diagnosis.
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ACNS1422
Disease: CNS
Who can participate?: Patients must be greater than or equal to 3 years and less than 22 years of age at the time of enrollment. Patients must be newly diagnosed and have: Eligibility confirmed by rapid central pathology and molecular screening review on APEC14B1 (see Section 3.1): classical histologic type (non LC/A) WNT medulloblastoma, positive nuclear β-catenin by IHC, positive for CTNNB1 mutation, negative for MYC and MYCN by FISH.
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: LGG-1403 Untreated LGG
Disease: CNS
Who can participate?: Patients must be less than 21 years of age at study entry. Patients who are newly OR previously diagnosed with low grade glioma (LGG), who have not been treated with any modality besides surgery or corticosteroids. Untreated astrocytomas or other eligible tumors interpreted as low grade.
Lead Researcher: Diana S. Osorio, MD
Protocol ID: MIBG
Disease: NBL
Who can participate?: Patients must be between 12 months and 65 years at the time of study enrollment.
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: NMTRC014
Disease: NBL
Who can participate?: ≤ 30.99 years of age and classified as high risk by the criteria used by COG or SIOPEN at the time of diagnosis.
Lead Researcher: Keri A. Streby, MD